Stem Cell-Like Gene Expression in Ovarian Cancer Predicts Type II Subtype and Prognosis

• Matthew Schwede,

  Affiliation Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Dimitrios Spentzos,

  Affiliation Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• Stefan Bentink,

  Affiliations Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Exosome Diagnostics GmbH, Martinsried, Germany

  ⨯
• Oliver Hofmann,

  Affiliation Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• Benjamin Haibe-Kains,

  Affiliations Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Integrative Systems Biology, Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada

  ⨯
• David Harrington,

  Affiliations Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• John Quackenbush,

  Affiliations Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America, Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Aedín C. Culhane

  * E-mail: aedin@jimmy.harvard.edu

  Affiliations Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯